Latest news with #Celebrex
Time of India
16-07-2025
- Business
- Time of India
Zydus Lifesciences shares in focus after USFDA nod for Celecoxib capsules
Zydus Lifesciences shares will be in focus after the company received final approval from the United States Food and Drug Administration ( USFDA ) for its Celecoxib capsules , a medication used for pain management. The approval covers Celecoxib capsules in strengths of 50 mg, 100 mg, 200 mg, and 400 mg, the company said in a regulatory filing on Tuesday. The drug will be manufactured at Zydus Lifesciences' facility in Ahmedabad. Celecoxib, sold under the brand name Celebrex, is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation caused by conditions such as arthritis, ankylosing spondylitis, menstrual pain, and juvenile rheumatoid arthritis in children aged two years and above. According to IQVIA data, Celecoxib capsules recorded sales of $122.6 million in the US for the 12 months ending May 2025. With this approval, Zydus now has 428 ANDA approvals and has filed a total of 492 since it began the process in FY2003-04. Live Events In June, the USFDA issued two observations following an inspection conducted between June 9 and 18 at the company's oncology injectable manufacturing facility at SEZ 1 near Matoda, Ahmedabad. Zydus Lifesciences shares target price According to Trendlyne, the average target price for Zydus Lifesciences shares stands at Rs 967, indicating a potential downside of 1% from current levels. Of the 30 analysts tracking the stock, most have maintained a 'Hold' rating. Zydus Lifesciences shares performance Zydus Lifesciences shares are down 19% over the past year but have gained 63% over the last two years. The company's current market capitalisation is Rs 97,317 crore. ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Economic Times
16-07-2025
- Business
- Economic Times
Zydus Lifesciences shares in focus after USFDA nod for Celecoxib capsules
Zydus Lifesciences shares will be in focus after the company received final approval from the United States Food and Drug Administration (USFDA) for its Celecoxib capsules, a medication used for pain management. ADVERTISEMENT The approval covers Celecoxib capsules in strengths of 50 mg, 100 mg, 200 mg, and 400 mg, the company said in a regulatory filing on Tuesday. The drug will be manufactured at Zydus Lifesciences' facility in Ahmedabad. Celecoxib, sold under the brand name Celebrex, is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation caused by conditions such as arthritis, ankylosing spondylitis, menstrual pain, and juvenile rheumatoid arthritis in children aged two years and above. According to IQVIA data, Celecoxib capsules recorded sales of $122.6 million in the US for the 12 months ending May this approval, Zydus now has 428 ANDA approvals and has filed a total of 492 since it began the process in June, the USFDA issued two observations following an inspection conducted between June 9 and 18 at the company's oncology injectable manufacturing facility at SEZ 1 near Matoda, Ahmedabad. ADVERTISEMENT According to Trendlyne, the average target price for Zydus Lifesciences shares stands at Rs 967, indicating a potential downside of 1% from current levels. Of the 30 analysts tracking the stock, most have maintained a 'Hold' rating. ADVERTISEMENT Zydus Lifesciences shares are down 19% over the past year but have gained 63% over the last two years. The company's current market capitalisation is Rs 97,317 crore. (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times) ADVERTISEMENT (You can now subscribe to our ETMarkets WhatsApp channel)
&w=3840&q=100)
Business Standard
15-07-2025
- Business
- Business Standard
Zydus Lifesciences gets USFDA nod for its painkiller Celecoxib capsules
Zydus Lifesciences on Tuesday announced that it has received final approval from the United States Food and Drug Administration (USFDA) for its painkiller medicine capsule named Celebrex (Celecoxib capsules). The company said that the medicine is used to treat pain or inflammation caused by many conditions such as arthritis, ankylosing spondylitis, and menstrual pain, along with juvenile rheumatoid arthritis in children who are at least 2 years old. The capsules will be produced at Zydus Lifesciences Ltd, Ahmedabad. Celecoxib capsules had sales of $122.6 million in the US in the 12-month period ending May 2025. The clearance is important as earlier this year, the company came under scrutiny following surveillance inspections at its Gujarat facility by the USFDA. Later, the company said in a regulatory filing to NSE that 'the inspection concluded with six observations and none of them were related to data integrity." The company reported in May that its consolidated net profit slipped about 1 per cent year-on-year (Y-o-Y) to ₹1,171 crore in the March quarter of financial year 2025 (Q4FY25); however, revenue soared 18 per cent Y-o-Y to ₹6,527.9 crore. The company is yet to file its earnings report for the first quarter of FY26.
Time of India
04-05-2025
- Health
- Time of India
Turmeric to cinnamon: Common herbs and spices you shouldn't mix with your medicine
Herbs and spices have long been considered a natural and safe way to flavor your food, aid digestion and support immunity. While these centuries-old superfoods are still used as kitchen staple, and trusted for their potential to boost wellness and prevent chronic diseases like arthritis, Alzheimer's, and heart disease, one should exercise caution when combining them with certain medications. In particular, too much of these 5 popular spices should be avoided when taking certain medications. People on blood thinners, blood pressure medicines, and heart rhythm drugs especially need to be careful. Cinnamon A pinch of cinnamon may make your curry or tea flavoursome, but think twice before increasing its consumption, or taking a cinnamon supplement without a doctor's advice, as a new study has found it may interact with your medicine and lessen its effect. A recent study published in Food Chemistry: Molecular Sciences has raised new concerns about how concentrated forms of cinnamon such as supplements or essential oils may interfere with the body's ability to process certain prescription medications. Researchers from the University of Mississippi's National Center for Natural Products Research simulated human digestion and investigated how cinnamon and its key chemical components like cinnamaldehyde, cinnamic acid, and cinnamon oil affect the body's xenobiotic receptors. These receptors help regulate how drugs are metabolized and cleared from the body. It was found that cinnamaldehyde and cinnamic acid activated these drug-processing receptors, which could lead the body to break down medications more quickly than intended. This may result in reduced drug effectiveness, especially for medications that require steady levels in the bloodstream to be effective. Ginger Any spice added in limited quantity to food is unlikely to cause any harm. It's the overdose of it that one must be cautious about. Ginger in recommended amounts is known to ease nausea, reduce inflammation, boost digestion, and control cholesterol and blood pressure. However, excess of this beneficial spice, can harm your health, especially if you are on blood thinners. People on anticoagulant therapy - blood thinners such as warfarin, aspirin and others - should seek advice from their healthcare experts regarding their ginger consumption. While having a cup of ginger tea or using it in your recipe, may not be harmful, too much of it can be risky. Besides, large amounts of ginger may affect insulin and lower blood sugar. Licorice Licorice root, not to be confused with licorice-flavored candy, can interact with a wide range of medications and may pose serious health risks if not consumed with caution. It has been shown to raise blood pressure and interfere with heart and blood pressure medications. The herb may also affect how the liver processes various drugs, including common pain relievers and anti-inflammatory medications like celecoxib (Celebrex), diclofenac (Voltaren), and ibuprofen (Advil, Motrin), as well as medications like glipizide for diabetes and fluvastatin for cholesterol. Women taking oral contraceptives have reported increased blood pressure and lowered potassium levels when combining them with licorice. It can also intensify the effects of certain antidepressants and corticosteroids, leading to heightened side effects. In people using stimulant laxatives, licorice can exacerbate potassium loss, which may be harmful. Additionally, it may interfere with blood sugar levels in those taking insulin or diabetes medications, and reduce the effectiveness of blood thinners, increasing the risk of clotting. St John's Wort Commonly taken as a natural remedy for mild to moderate depression, St. John's Wort can significantly interfere with many medications, says study . It can reduce the effectiveness of antidepressants, leading to potential worsening of mood symptoms. It may also lower the efficacy of birth control pills, increase the risk of unplanned pregnancy, and affect the performance of blood thinners, immunosuppressants, and certain heart medications. This herb speeds up how the liver breaks down drugs, which can reduce their concentration in the body and make them less effective. Turmeric Turmeric in your curry is fine, but you should think twice when taking supplements. Too much of it can interact with your medicine. This happens due to the spice's active component called curcumin, which may pose risks when combined with certain medications. One key concern is its potential to increase bleeding risk when taken alongside blood thinners such as warfarin, aspirin, or clopidogrel, says study . While turmeric is generally safe to add in your food, concentrated supplements can amplify these effects, making it important for those on anticoagulants or upcoming surgeries to consult a healthcare provider before use. Combat Monsoon Cold & Cough: Here's A Quick Fix With Indian Borage Leaf And Turmeric Masterclass for Students. Upskill Young Ones Today!– Join Now
Reuters
27-02-2025
- Business
- Reuters
Drugmaker Viatris forecasts weak 2025 results after import curbs on India plant
Feb 27 (Reuters) - Viatris (VTRS.O), opens new tab forecast annual revenue and profit below Wall Street estimates on Thursday, two months after the U.S. health regulator restricted imports from one of the drugmaker's key plants in India. Shares of Viatris fell 14.6% in premarket trading. Viatris in December 23, 2024 disclosed that the U.S. Food and Drug Administration (FDA) has restricted imports of 11 products from its facility in Indore, India due to violations of federal requirements. The company estimated on Thursday that the FDA action will reduce its 2025 total revenues by about $500 million and adjusted core earnings by about $385 million. "Although in the past we and investors had assumed a minimal impact from Indore warning letter, today's guidance shows a significant negative impact," said Ashwani Verma, an analyst at brokerage UBS. The Canonsburg, Pennsylvania-based Viatris forecast 2025 revenue between $13.5 billion and $14 billion, below analysts' estimates of $14.27 billion, according to data compiled by LSEG. The company expects 2025 adjusted earnings per share between $2.12 and $2.26, compared with estimates of $2.59. The FDA has permitted exceptions for four Viatris products due to shortage concerns, though the specific products have not been disclosed. Viatris, formed through the merger of generic drugmaker Mylan and Pfizer's (PFE.N), opens new tab Upjohn business in 2020, has generic and branded drugs in its portfolio, including erectile dysfunction drug Viagra, anti-anxiety medication Xanax, epilepsy treatment Lyrica and arthritis treatment Celebrex. The drugmaker also fell short of market expectations for fourth-quarter revenue and profit. On an adjusted basis, the company reported a profit of 54 cents per share, compared with analysts' estimates of 57 cents per share, according to data compiled by LSEG. It reported a revenue of $3.52 billion for the fourth quarter, compared with analysts' average estimate of $3.61 billion.
